Comparing effects of different routes of heparin administration on the serum biomarkers of thrombosis
Abstract
Background: Association between thrombosis pathogenesis and inflammatory conditions has been reported. Also inflammatory biomarkers have been proposed for prediction of thrombosis events. Objectives: Effects of different methods of heparin administration (subcutaneous vs continuous infusion) as thromboprophylaxis on the biomarkers of thrombosis have been evaluated. Methods: Serum levels of hsCRP, IL-10 and P-selectin as the biomarkers of thrombosis were measured at baseline, days 3 and 7 during the patients’ hospitalization period. Results: Changes in the serum levels of thrombosis biomarkers (hsCRP, IL-10 and P-selectin) were comparable between the subcutaneous and continuous infusion groups. Conclusion: Both subcutaneous injection and continuous infusion of heparin as thromboprophylaxis showed same effects on the thrombosis biomarkers.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Attia J, Ray JG, Cook DJ, Douketis J, Ginsberg JS, Geerts WH. Deep vein thrombosis and its prevention in critically ill adults. Arch Intern. Med. 161, 1268–1279 (2001).
2.
Geerts W, Selby R. Prevention of venous thromboembolism in the ICU. Chest 124(6 Suppl.), 357S–363S (2003).
3.
Cook DJ, Crowther MA, Meade MO, Douketis J. Prevalence, incidence, and risk factors for venous thromboembolism in medical-surgical intensive care unit patients. J. Crit. Care 20(4), 309–313 (2005).
• Venous thromboembolism in medical–surgical intensive care unit patients.
4.
Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl.), e419S–e494S (2012).
• Guideline of antithrombotic and thrombolytic therapy.
5.
Lim W, Meade M, Lauzier F et al. Failure of anticoagulant thromboprophylaxis: risk factors in medical–surgical critically ill patients. Crit. Care Med. 43(2), 401–410 (2015).
6.
Izadpanah M, Khalili H, Dashti-Khavidaki S, Mohammadi M. Heparin and related drugs for venous thromboembolism prophylaxis: subcutaneous or intravenous continuous infusion? J. Comp. Eff. Res. 4(2), 167–184 (2015).
•• Review of heparin and related drugs for venous thromboembolism prophylaxis.
7.
F Shepherd M, Rosborough TK, Schwartz ML. Unfractionated heparin infusion for thromboprophylaxis in highest risk gastric bypass surgery. Obes. Surg. 14, 601–605 (2004).
8.
Quebbemann B, Akhondzadeh M, Dallal R. Continuous intravenous heparin infusion prevents peri-operative thromboembolic events in bariatric surgery patients. Obes. Surg. 15, 1221–1224 (2015).
9.
Cossu ML, Pilo L, Piseddu G, Tilocca PL, Cossu F, Noya G. Prophylaxis of venous thromboembolism in bariatric surgery. Chir. Ital. 59(3), 331–335 (2007).
10.
Ikesaka R, Delluc A, Le Gal G, Carrier M. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thromb. Res. 133(4), 682–687 (2014).
11.
Cheng SS, Nordenholz K, Matero D et al. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Inten. Care Med. 38(4), 642–648 (2012).
12.
Robinson S, Zincuk A, Strøm T, Larsen TB, Rasmussen B, Toft P. Enoxaparin, effective dosage for intensive care patients: double-blinded, randomised clinical trial. Crit. Care 14(2), R41 (2010).
13.
Robinson S, Zincuk A, Larsen UL et al. A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial. Crit. Care 17(2), R75 (2013).
•• Comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients.
14.
Lim SY, Jeon K, Kim H-J et al. AntifactorXa Levels in critically ill Korean patients receiving enoxaparin for thromboprophylaxis: a prospective observational study. J. Korean Med. Sci. 28(3), 466–471 (2013).
15.
Dörffler-Melly J, de Jonge E, Pont AC et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359, 849–850 (2002).
16.
Rommers MK, Van der Laan N, Egberts TC, van den Bemt PM. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit. Care 10, R93 (2006).
17.
Page C. Heparin and related drugs: beyond anticoagulant activity. ISRN Pharmacol. 2013, 910743 (2013).
• Beyond anticoagulant activity of heparin.
18.
Mousavi S, Moradi M, Khorshidahmad T, Motamedi M. Anti-inflammatory effects of heparin and its derivatives: a systematic review. Adv. Pharmacol. Sci. (2015) (Epub ahead of print).
19.
Alban S. Adverse effects of heparin. In: Heparin - A Century of Progress. Handbook of Experimental Pharmacology. Lever R, Mulloy B, Page CP (Eds). Springer, Berlin Heidelberg, 211–263 (2012).
20.
Fox EA, Susan RK. The relationship between inflammation and venous thrombosis. Thromb. Haemost. 94(2), 362–365 (2005).
21.
Hou H, Ge Z, Ying P et al. Biomarkers of deep venous thrombosis. J. Thromb. Thrombolysis 34(3), 335–346 (2012).
• Biomarkers of deep venous thrombosis.
22.
Barnes DM, Wakefield TW, Rectenwald JE. Novel biomarkers associated with deep venous thrombosis: a comprehensive review. Biomark. Insights 3, 93–100 (2008).
23.
Wells PS, Anderson DR, Rodger M et al. Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N. Engl. J. Med. 349(13), 1227–35 (2003).
24.
Decousus H, Tapson VF, Bergmann JF et al. Factors at admission associated with bleeding risk in medical patients: findings from the IMPROVE investigators. Chest 139(1), 69–79 (2011).
25.
Stasko J, Galajda P, Ivankova J, Holly P, Rozborilova E, Kubisz P. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment. Clin. Appl. Thromb. Hemost. 13(4), 410–415 (2007).
26.
Chiu CA, Wu CJ, Yang CH et al. Levels and value of soluble P-selectin following acute myocardial infarction: evaluating the link between soluble P-selectin levels and recruitment of circulating white blood cells and the marker for the rapid diagnosis of chest pain. Chang Gung Med. J. 28(10), 699–707 (2005).
27.
Liu WH, Yang CH, Yeh KH et al. Circulating levels of soluble P-selectin in patients in the early and recent phases of myocardial infarction. Chang Gung Med. J. 28(9), 613–620 (2005).
28.
Lever R, Page C. Non-anticoagulant effects of heparin: an overview. In: Heparin - A Century of Progress. Handbook of Experimental Pharmacology. Lever R, Mulloy B, Page CP (Eds). Springer, Berlin Heidelberg, 281–305 (2012).
29.
Skinner MP, Lucas CM, Burns GF, Chesterman CN, Berndt MC. GMP-140 binding to neutrophils is inhibited by sulfated glycans. J. Biol. Chem. 266, 5371–5374 (1991).
30.
Stevenson JL, Choi SH, Varki A. Differential metastasis inhibition by clinically relevant levels of heparins – correlation with selectin inhibition, not antithrombotic activity. Clin. Cancer Res. 11, 7003–7011 (2005).
31.
Mayr AJ, Dünser M, Jochberger S et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb. Res. 105, 201–204 (2002).
32.
Priglinger U, DelleKarth G, Geppert A et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit. Care Med. 31, 1405–1409 (2003).
33.
Malinoski D, Jafari F, Ewing T et al. Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. J. Trauma 68(4), 874–880 (2010).
34.
Levi M. Adequate thromboprophylaxis in critically ill patients. Crit. Care 14(2), 142 (2010).
35.
Rectenwald JE, Myers DD Jr, Hawley AE et al. D-dimer, P-selectin, and microparticles: novel markers to predict deep venous thrombosis. A pilot study. Thromb. Haemost. 94(6), 1312–1317 (2005).
36.
Smith A, Quarmby JW, Collins M, Lockhart SM, Burnand KG. Changes in the levels of soluble adhesion molecules and coagulation factors in patients with deep vein thrombosis. Thromb. Haemost. 82(6), 1593–1599 (1999).
37.
Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br. J. Haematol. 108(1), 191–193 (2000).
38.
Ay C, Jungbauer LV, Sailer T et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin. Chem. 53, 1235–1243 (2007).
39.
Ay C, Simanek R, Vormittag R et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood 112, 2703–2708 (2008).
40.
Wang L, Liu GJ, Chen YX, Dong HP, Zhang YQ, Wang LX. Combined use of D-dimer and P-selectin for the diagnosis of splenic or portal vein thrombosis following splenectomy. Thromb. Res. 125, e206–e209 (2010).
41.
Ramacciotti E, Blackburn S, Hawley AE et al. Evaluation of soluble P-selectin for the diagnosis of deep venous thrombosis. Clin. Appl. Thromb. Hemost. 17(4), 425–431 (2011).
42.
Shi D, Xu X, Xu Z et al. P-selectin: an unpredicted factor for deep vein thrombosis after total hip arthroplasty. BioMed. Res. Int. 2014, 783967 (2014).
43.
Caligiuri G, Rudling M, Ollivier V et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol. Med. 9(1), 10–17 (2003).
44.
Downing LJ, Strieter RM, Kadell AM et al. IL-10 regulates thrombus-induced vein wall inflammation and thrombosis. J. Immunol. 161, 1471–1476 (1998).
45.
Cochery-Nouvellon E, Vitry F, Cornillet-Lefebvre P, Hezard N, Gillot L, Nguyen P. Interleukin-10 promoter polymorphism and venous thrombosis: a case–control study. Thromb. Haemost. 96(1), 24–28 (2006).
46.
Poredos P, Jezovnic MK. In patients with idiopathic venous thrombosis, interleukin-10 is decreased and related to endothelial dysfunction. Heart Vessels 26(6), 596–602 (2011).
47.
Du T, Tan Z. Relationship between deep venous thrombosis and inflammatory cytokines in postoperative patients with malignant abdominal tumors. Braz. J. Med. Biol. Res. 47(11), 1003–1007 (2014).
48.
Ridker PM, Cushman M, Stampfer MJ et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979 (1997).
49.
Tsai AW, Cushman M, Rosamond WD et al. Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am. J. Med. 113, 636–642 (2002).
50.
Wong NA, Laitt RD, Goddard PR et al. Serum C reactive protein does not reliably exclude lower limb deep venous thrombosis. Thromb. Haemost. 76, 816–817 (1996).
51.
Maskell NA, Butland RJ. A normal serum CRP measurement does not exclude deep vein thrombosis. Thromb. Haemost. 86, 1582–1583 (2001).
52.
Bucek RA, Reiter M, Quehenberger P et al. C-reactive protein in the diagnosis of deep vein thrombosis. Br. J. Haematol. 119, 385–389 (2002).
53.
Vormittag R, Vukovich T, Schonauer V et al. Basal high-sensitivity-C-reactive protein levels in patients with spontaneous venous thromboembolism. Thromb. Haemost. 93(3), 488–493 (2005).
54.
Hald EM, Brækkan SK, Mathiesen EB et al. High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism. Haematologica 96(8), 1189–1194 (2001).
Information & Authors
Information
Published In
Copyright
© Future Medicine Ltd.
History
Published online: 19 April 2016
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Comparing effects of different routes of heparin administration on the serum biomarkers of thrombosis. (2016) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2015-0013
Export citation
Select the citation format you wish to export for this article or chapter.